Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.51 |
| ▸ | LTA4H | P09960 | 2/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.49 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.49 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.49 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31469369 | 0.89 | MEN1 (0.54) | KDM4ESIGMAR1HRH3LTA4H | |
| SCHEMBL4507750 | 0.88 | KDM4E (0.61) | KDM4ESIGMAR1LTA4HNPC1TSHR | |
| SCHEMBL4424443 | 0.85 | MAP4K4 (0.56) | SIGMAR1HRH3LTA4HPTGS2PSMB1 | |
| SCHEMBL31298956 | 0.83 | MAP4K4 (0.57) | KDM4ESIGMAR1HRH3LTA4HPTGS2 | |
| SCHEMBL4416516 | 0.83 | MAP4K4 (0.57) | KDM4ESIGMAR1HRH3LTA4HPTGS2 | |
| SCHEMBL4505427 | 0.82 | HRH3 (0.54) | KDM4ESIGMAR1HRH3NPC1RAB9A | |
| SCHEMBL4506955 | 0.81 | SRC (0.59) | KDM4ESIGMAR1HRH3GRM4 | |
| Hydrochloric Acid SCHEMBL7865977 | 0.81 | SRC (0.58) | KDM4ESIGMAR1HRH3GRM4 | |
| SCHEMBL3364377 | 0.79 | HRH3 (0.53) | SIGMAR1HRH3PSMB1PSMB5PSMB2 | |
| SCHEMBL3424568 | 0.78 | PDE4A (0.44) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1309569-B1 | N-aryl-{4-[7-(alkoxy)quinazolin-4-yl]piperazinyl}carboxamide derivatives as PDGFRs inhibitors | MILLENNIUM PHARM INC (US) | 2010-10-06 | — | — | EP | disclosed |
| US-20060063770-A1 | Nitrogenous heterocyclic compounds | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-03-23 | — | — | US | disclosed |
| US-6956039-B2 | Nitrogenous heterocylic compounds | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-10-18 | — | — | US | disclosed |
| US-20040186110-A1 | Nitrogenous heterocylic compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2004-09-23 | — | — | US | disclosed |
| EP-1309569-A2 | NITROGENOUS HETEROCYCLIC COMPOUNDS | Millennium Pharmaceuticals, Inc. (US) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002016362-A2 | NITROGENOUS HETEROCYCLIC COMPOUNDS | COR THERAPEUTICS, INC. (US) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063770-A1 | Nitrogenous heterocyclic compounds | WNK2, CDK5, WNK1 | KDM4E 3139/4885POLB 2847/4885SIGMAR1 1369/4885 |
| US-20040186110-A1 | Nitrogenous heterocylic compounds | WNK2, CDK5, WNK1 | KDM4E 2910/4885POLB 3158/4885SIGMAR1 1354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.